Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Serotonin Syndrome with Exposure from Tetrahydrocannabinol: a Case Report to Highlight the Side Effects of Increasing Use of CBD Products
Neuro Trauma, Critical Care, and Sports Neurology
P15 - Poster Session 15 (12:00 PM-1:00 PM)
13-004
N/A

Serotonin syndrome is a potentially life-threatening condition caused by over-activation of the serotonin (5-HT) system in the CNS. This can occur with the therapeutic use of serotonergic agents or inadvertent complex drug interactions between serotonergic agents. Clinical presentation varies widely in severity and is diagnosed by the decision rules of Hunter Serotonin Toxicity Criteria, utilizing the three main clinical categories: altered mental status, autonomic hyperactivity, and neuromuscular abnormalities.

A 63 year-old male with medical history most notable for restless leg syndrome (on ropinirole), chronic lymphocytic leukemia, depression on duloxetine, and chronic alcohol abuse presented with altered mental status, shaking, diaphoresis, and an inability to walk. He had initiated intake of THC-infused cheese as a neuropathic pain control measure. On examination, he was afebrile, hypertensive and mildly tachycardic, somnolent, diaphoretic, and diffusely hyperreflexic. Urine toxicology screen was positive for tetrahydrocannabinol (THC). He was treated with intravenous fluids and lorazepam with improvement of symptoms. With continued supportive therapy and discontinuation of duloxetine, the patient completely recovered within 48 hours and was discharged home without residual symptoms.

N/A

The cannabinoid (CB) receptors and endogenous agonists are widely distributed throughout the CNS and are involved in the regulation of mood. This endocannabinoid system is known to regulate serotonergic system through several mechanisms: modulation of 5-HT release, receptor expression, and regulation of excitability of 5-HT neurons.

With the legalization of marijuana and increasing access to cannabinoid-containing products, it is imperative to raise awareness of the serotonergic effects of these products and to educate patients to avoid use of these products if they are currently taking a serotonergic agent. Complete workup of a patient with serotonin syndrome should include a urine drug screen and comprehensive social history.

Authors/Disclosures

PRESENTER
No disclosure on file
No disclosure on file
Ava Giugliano, DO No disclosure on file
Aarti Sarwal, MD, FÂé¶¹´«Ã½Ó³»­ Dr. Sarwal has received personal compensation in the range of $0-$499 for serving as a Consultant for Stimdia, Inc. Dr. Sarwal has received personal compensation in the range of $0-$499 for serving as a Consultant for Sheinkei. Dr. Sarwal has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Society of Critical Care Medicine . Dr. Sarwal has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Society of Neuroimaging . The institution of Dr. Sarwal has received research support from Butterfly, Inc. The institution of Dr. Sarwal has received research support from Bard. The institution of Dr. Sarwal has received research support from Biogen. The institution of Dr. Sarwal has received research support from Novartis. The institution of Dr. Sarwal has received research support from CVR Global. The institution of Dr. Sarwal has received research support from NIH/NIA R01 AG066910-01 . The institution of Dr. Sarwal has received research support from Image Monitoring. Dr. Sarwal has received personal compensation in the range of $500-$4,999 for serving as a Speaker/Faculty, CME courses with Society of Critical Care Medicine . Dr. Sarwal has received personal compensation in the range of $500-$4,999 for serving as a Speaker at annual congress with Intensive Care Society. Dr. Sarwal has received personal compensation in the range of $500-$4,999 for serving as a Speaker at annual congress with Indian Society of Critical Care. Dr. Sarwal has received personal compensation in the range of $500-$4,999 for serving as a speaker/Faculty for Annual meeting, travel compensation with European Society of Intensive Care Medicine. Dr. Sarwal has received personal compensation in the range of $500-$4,999 for serving as a Speaker with ISICEM. Dr. Sarwal has a non-compensated relationship as a Social Media Editor with Neurocritical Care that is relevant to Âé¶¹´«Ã½Ó³»­ interests or activities. Dr. Sarwal has a non-compensated relationship as a Secretary with American Society of Neuroimaging that is relevant to Âé¶¹´«Ã½Ó³»­ interests or activities. Dr. Sarwal has a non-compensated relationship as a President with Association of Indian Neurologists in America that is relevant to Âé¶¹´«Ã½Ó³»­ interests or activities. Dr. Sarwal has a non-compensated relationship as a Member, Board of Directors with Neurocritical Care Society that is relevant to Âé¶¹´«Ã½Ó³»­ interests or activities. Dr. Sarwal has a non-compensated relationship as a Section Chair, Neurosciences Section with Society of Critical Care Medicine that is relevant to Âé¶¹´«Ã½Ó³»­ interests or activities.